Ligand Pharmaceuticals LGND Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's retained earnings?
- Ligand Pharmaceuticals (LGND) reported retained earnings of $594.74M in Q1 2026.
- How has Ligand Pharmaceuticals's retained earnings changed year-over-year?
- Ligand Pharmaceuticals's retained earnings increased by 30.3% year-over-year, from $456.53M to $594.74M.
- What is the long-term trend for Ligand Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's retained earnings has grown at a 9.2% compound annual growth rate (CAGR), from $391.95M to $608.09M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.